# US 2004/0082022 A1 · Solutions for use as plasma expanders and substitutes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082022 A1
- Document ID: US20040082022A1
- Status: Published application
- Kind: A1
- Application number: 10/641,401
- Filed: 2003-08-13
- Published: 2004-04-29
- Earliest claimed: 1993-06-04
- Inventors: Paul E. Segall; Hal Sternberg; Harold D. Waitz; Judith M. Segall
- Web page: https://patentgrep.com/patent/US20040082022A1

## CPC

- A61K 9/0026: {Blood substitute; Oxygen transporting formulations; Plasma extender}
- A01N 1/10: Preservation of living parts
- A01N 1/12: Chemical aspects of preservation
- A01N 1/126: Physiologically active agents, e.g. antioxidants or nutrients
- A01N 1/162: Temperature processes, e.g. following predefined temperature changes over time
- A61K 33/10: Carbonates; Bicarbonates
- A61K 33/14: Alkali metal chlorides; Alkaline earth metal chlorides
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS

## Abstract

An artificial plasma-like substance having at least one water soluble polysaccharide oncotic agent selected from the group consisting of high molecular weight hydroxyethyl starch, low molecular weight hydroxyethyl starch, dextran 40 and dextran 70, which is buffered by lactate and has a pre-administration pH of between 4 and 6.5 is disclosed. In one embodiment, the artificial plasma-like solution may have at least two water soluble polysaccharide oncotic agents one of which is eliminated from the circulation slowly and the other of which is eliminated from the circulation quickly. Supplementation of the plasma-like solution with certain ions is described. A system for administration of the plasma-like solution to a subject wherein the system comprises a first and second solution each having particular buffers is described. Methods for the administration of the plasma-like solution are also disclosed.

## Claims

### Claim 1

A method for increasing the circulating volume of a hypovolemic subject comprising administering to said subject a plasma-like substance comprising an aqueous solution of at least one water soluble polysaccharide oncotic agent and a small organic acid salt, with the proviso that:
(a) when said oncotic agent is a hydroxyethyl starch, said hydroxyethyl starch is selected from the group consisting of high molecular weight and low molecular weight hydroxyethyl starches; and
(b) said solution has at least one of the following characteristics:
(i) is terminally heat sterilized;
(ii) does not contain a biological buffer; and
(iii) has a pH between 4 and 6.5.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said polysaccharide oncotic agent is a glucan polymer.

### Claim 3 (depends on 2)

The method according to claim 2, wherein said glucan polymer is a hydroxyethyl starch.

### Claim 4 (depends on 3)

The method according to claim 3, wherein said hydroxyethyl starch has a molar substitution of 0.7.

### Claim 5 (depends on 3)

The method according to claim 3, wherein said hydroxyethyl starch has a molar substitution of 0.45.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said small organic acid salt is a salt of a small organic acid ion that may be metabolized.

### Claim 7 (depends on 6)

The method according to claim 6, wherein said small organic acid ion is selected from the group consisting lactate, acetate, pyruvate, gluconate and succinate.

### Claim 8 (depends on 1)

The method according to claim 1, wherein said solution does not comprise a biological buffer.

### Claim 9 (depends on 1)

The method according to claim 1, wherein said solution is a terminally heat sterilized solution.

### Claim 10 (depends on 1)

The method according to claim 1, wherein said solution has a pH between 4 and 6.5.

### Claim 11

A method for increasing the circulating volume of a hypovolemic subject comprising administering to said subject a plasma-like substance comprising an aqueous solution of at least one water soluble hydroxyethyl starch selected from the group consisting of high and low molecular weight hydroxyethyl starches and a small organic acid salt of an ion selected from the group consisting of lactate, acetate, pyruvate, gluconate and succinate, wherein said solution has a pH between 4 and 6.5.

### Claim 12 (depends on 11)

The method according to claim 11, wherein said hydroxyethyl starch has a molar substitution of 0.7.

### Claim 13 (depends on 12)

The method according to claim 12, wherein said hydroxyethyl starch is hetastarch.

### Claim 14 (depends on 11)

The method according to claim 11, wherein said hydroxyethyl starch has a molar substitution of 0.45.

### Claim 15 (depends on 14)

The method according to claim 14, wherein said hydroxyethyl starch is pentastarch.

### Claim 16 (depends on 11)

The method according to claim 11, wherein said solution does not comprise a biological buffer.

### Claim 17 (depends on 11)

The method according to claim 11, wherein said solution is a terminally heat sterilized solution.

### Claim 18

A plasma-like substance comprising an aqueous solution of at least one water soluble polysaccharide oncotic agent and a small organic acid salt, with the proviso that:
(a) when said oncotic agent is a hydroxyethyl starch, said hydroxyethyl starch is selected from the group consisting of high molecular weight and low molecular weight hydroxyethyl starches; and
(b) said solution has at least one of the following characteristics:
(i) is terminally heat sterilized;
(ii) does not contain a biological buffer; and
(iii) has a pH between 4 and 6.5.

### Claim 19 (depends on 18)

The plasma-like substance according to claim 18, wherein said polysaccharide oncotic agent is a glucan polymer.

### Claim 20 (depends on 19)

The plasma-like substance according to claim 19, wherein said glucan polymer is a hydroxyethyl starch.

### Claim 21 (depends on 20)

The plasma-like substance according to claim 20, wherein said hydroxyethyl starch has a molar substitution of 0.7.

### Claim 22 (depends on 20)

The plasma-like substance according to claim 20, wherein said hydroxyethyl starch has a molar substitution of 0.45.

### Claim 23 (depends on 18)

The plasma-like substance according to claim 18, wherein said small organic acid salt is a salt of a small organic acid ion that may be metabolized.

### Claim 24 (depends on 23)

The plasma-like substance according to claim 23, wherein said small organic acid ion is selected from the group consisting lactate, acetate, pyruvate, gluconate and succinate.

### Claim 25 (depends on 18)

The plasma-like substance according to claim 18, wherein said solution does not comprise a biological buffer.

### Claim 26 (depends on 18)

The plasma-like substance according to claim 18, wherein said solution is a terminally heat sterilized solution.

### Claim 27 (depends on 18)

The plasma-like substance according to claim 18, wherein said solution has a pH between 4 and 6.5.

### Claim 28

A plasma-like substance comprising an aqueous solution of at least one water soluble hydroxyethyl starch selected from the group consisting of high and low molecular weight hydroxyethyl starches and a small organic acid salt of an ion selected from the group consisting of lactate, acetate, pyruvate, gluconate and succinate, wherein said solution has a pH between 4 and 6.5.

### Claim 29 (depends on 28)

The plasma-like substance according to claim 28, wherein said hydroxyethyl starch has a molar substitution of 0.7.

### Claim 30 (depends on 29)

The plasma-like substance according to claim 29, wherein said hydroxyethyl starch is hetastarch.

### Claim 31 (depends on 28)

The plasma-like according to claim 28, wherein said hydroxyethyl starch has a molar substitution of 0.45.

### Claim 32 (depends on 31)

The plasma-like according to claim 31, wherein said hydroxyethyl starch is pentastarch.

### Claim 33 (depends on 28)

The plasma-like according to claim 28, wherein said solution does not comprise a biological buffer.

### Claim 34 (depends on 28)

The plasma-like according to claim 28, wherein said solution is a terminally heat sterilized solution.
